Insider Selling: Natera (NASDAQ:NTRA) CEO Sells $32,134,171.88 in Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 160,703 shares of the business’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $199.96, for a total value of $32,134,171.88. Following the completion of the transaction, the chief executive officer directly owned 144,816 shares in the company, valued at approximately $28,957,407.36. This represents a 52.60% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Tuesday, October 28th, Steven Leonard Chapman sold 3,680 shares of Natera stock. The stock was sold at an average price of $191.46, for a total value of $704,572.80.
• On Monday, October 27th, Steven Leonard Chapman sold 2,335 shares of Natera stock. The stock was sold at an average price of $192.32, for a total value of $449,067.20.
• On Tuesday, October 21st, Steven Leonard Chapman sold 1,603 shares of Natera stock. The stock was sold at an average price of $187.95, for a total value of $301,283.85.
• On Wednesday, October 1st, Steven Leonard Chapman sold 14,083 shares of Natera stock. The stock was sold at an average price of $160.00, for a total value of $2,253,280.00.
• On Tuesday, September 30th, Steven Leonard Chapman sold 9,109 shares of Natera stock. The stock was sold at an average price of $162.05, for a total value of $1,476,113.45.
• On Tuesday, September 2nd, Steven Leonard Chapman sold 5,079 shares of Natera stock. The stock was sold at an average price of $166.53, for a total value of $845,805.87.

Natera Price Performance

Shares of NASDAQ NTRA opened at $199.92 on Thursday. Natera, Inc. has a one year low of $123.61 and a one year high of $203.23. The business’s fifty day moving average price is $176.51 and its 200-day moving average price is $163.03. The stock has a market capitalization of $27.44 billion, a PE ratio of -104.67 and a beta of 1.75.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The firm had revenue of $546.60 million for the quarter, compared to analysts’ expectations of $476.84 million. During the same period in the prior year, the company earned ($0.30) EPS. The firm’s quarterly revenue was up 32.2% on a year-over-year basis. As a group, equities analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

NTRA has been the topic of a number of recent research reports. Canaccord Genuity Group reaffirmed a “buy” rating and set a $200.00 price target on shares of Natera in a research report on Tuesday, October 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research report on Wednesday, October 8th. Wells Fargo & Company initiated coverage on Natera in a research report on Monday, September 22nd. They set an “equal weight” rating and a $175.00 price target on the stock. Morgan Stanley reaffirmed an “overweight” rating and set a $195.00 price target on shares of Natera in a research report on Sunday, August 10th. Finally, Barclays reiterated an “overweight” rating and set a $210.00 price objective (up from $190.00) on shares of Natera in a research note on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Natera has a consensus rating of “Moderate Buy” and a consensus target price of $194.89.

Hedge Funds Weigh In On Natera

A number of institutional investors have recently added to or reduced their stakes in the business. Guided Capital Wealth Management LLC increased its stake in Natera by 0.5% in the 2nd quarter. Guided Capital Wealth Management LLC now owns 13,135 shares of the medical research company’s stock worth $2,219,000 after acquiring an additional 66 shares during the last quarter. Main Management ETF Advisors LLC increased its stake in Natera by 1.7% in the 2nd quarter. Main Management ETF Advisors LLC now owns 4,398 shares of the medical research company’s stock worth $743,000 after acquiring an additional 72 shares during the last quarter. Yousif Capital Management LLC increased its position in shares of Natera by 4.5% during the 3rd quarter. Yousif Capital Management LLC now owns 1,682 shares of the medical research company’s stock valued at $271,000 after purchasing an additional 72 shares during the last quarter. Wedmont Private Capital increased its position in shares of Natera by 4.9% during the 2nd quarter. Wedmont Private Capital now owns 1,580 shares of the medical research company’s stock valued at $256,000 after purchasing an additional 74 shares during the last quarter. Finally, Gries Financial LLC increased its position in shares of Natera by 4.0% during the 3rd quarter. Gries Financial LLC now owns 1,904 shares of the medical research company’s stock valued at $306,000 after purchasing an additional 74 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.